Analyst Price Targets — AMRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 7, 2026 12:20 pm | — | Truist Financial | $15.00 | $12.99 | TheFly | Amneal Pharmaceuticals price target raised to $15 from $14 at Truist |
| December 8, 2025 9:24 pm | — | Barclays | $15.00 | $11.87 | TheFly | Amneal Pharmaceuticals initiated with an Overweight at Barclays |
| March 3, 2025 11:25 am | — | Barclays | $11.00 | $8.76 | TheFly | Amneal Pharmaceuticals price target raised to $11 from $10 at Barclays |
| November 11, 2024 12:22 pm | David Amsellem | Piper Sandler | $11.00 | $8.29 | StreetInsider | Amneal Pharmaceuticals (AMRX) PT Raised to $11 at Piper Sandler |
| October 2, 2024 8:53 am | Les Sulewski | Truist Financial | $12.00 | $8.70 | TheFly | Amneal Pharmaceuticals price target raised to $12 from $10 at Truist |
| October 1, 2024 1:42 pm | Les Sulewski | Truist Financial | $10.00 | $8.70 | StreetInsider | Truist Securities Reiterates Buy Rating on Amneal Pharmaceuticals (AMRX) |
| May 3, 2024 1:57 pm | Les Sulewski | Truist Financial | $9.00 | $6.76 | StreetInsider | Amneal Pharmaceuticals (AMRX) PT Raised to $9 at Truist Securities |
| March 21, 2024 8:43 am | David Amsellem | Piper Sandler | $8.00 | $6.29 | StreetInsider | Amneal Pharmaceuticals (AMRX) PT Raised to $8 at Piper Sandler |
| August 8, 2022 8:55 am | — | Goldman Sachs | $4.00 | $3.22 | Benzinga | Goldman Sachs Maintains Buy on Amneal Pharmaceuticals, Lowers Price Target to $4 |
Latest News for AMRX
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.12 per share a year ago.
‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million ; GAAP Net Income of $35 million ; Diluted Income per Share of $0.11 ‒ ‒ Q4 2025 Adjusted Net Income of $68 million , Adjusted EBITDA of $175 million ; Adjusted Diluted EPS of $0.21 ‒ ‒ Full Year 2025 Net Revenue of $3.02 billion ; GAAP Net Income of $72 million ; Diluted…
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AMRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.